SCHEMBL6680959

SCHEMBL6680959

Cc1c2n(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)C=C(C(=O)O)NC2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
EDNRB P24530 1/20 0.35
EDNRA P25101 1/20 0.35
PTGS1 P23219 2/20 0.34
PTGS2 P35354 2/20 0.34
HTT P42858 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
BRD4 O60885 1/20 0.34
P2RY14 Q15391 1/20 0.33
KDM4E B2RXH2 1/20 0.33
RAB9A P51151 1/20 0.33
MDM4 O15151 1/20 0.33
MDM2 Q00987 1/20 0.33
SOS1 Q07889 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679307 0.85 TRPA1 (0.43) ALDH1A1TSHRL3MBTL1POLB
SCHEMBL6682928 0.85 TP53 (0.36) ALDH1A1TSHRL3MBTL1PTGDR2KDM4E
SCHEMBL6684992 0.85 TRPA1 (0.39) TSHRHTTKDM4ERAB9A
SCHEMBL6679418 0.80 PTGDR2 (0.36) ALDH1A1TSHRL3MBTL1PTGDR2PTGS1
SCHEMBL6679462 0.80 ALDH1A1 (0.36) ALDH1A1TSHRL3MBTL1PTGDR2PTGS1
SCHEMBL6684000 0.78 ABCB1 (0.35) ALDH1A1KDM4ERAB9APOLB
SCHEMBL6681574 0.70 ALDH1A1 (0.36) ALDH1A1TSHRL3MBTL1PTGDR2HTT
SCHEMBL6679240 0.70 TP53 (0.36) ALDH1A1TSHRL3MBTL1KDM4ERAB9A
SCHEMBL6683536 0.70 TRPA1 (0.45) ALDH1A1POLB
SCHEMBL6685075 0.70 TRPA1 (0.43) ALDH1A1TSHRL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US claimed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 ALDH1A1 430/4885TSHR 4060/4885L3MBTL1 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.